Supportive Care in Cancer

, Volume 21, Issue 7, pp 1879–1884

Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma

  • Steven C. Kao
  • Nico van Zandwijk
  • Peter Corte
  • Christopher Clarke
  • Stephen Clarke
  • Janette Vardy
Original Article

Abstract

Purpose

Malignant pleural mesothelioma (MPM) is considered a treatment-resistant disease. We determined the proportion of patients who received treatment in the last month of life and potential factors associated with use of chemotherapy at the end of life.

Methods

Consenting MPM patients compensated by the Dust Diseases Board (DDB) were included. Patient, treatment and outcome details were obtained through the DDB, treating physicians and Medicare Australia. The association between potential factors (age, gender, geographical location, disease stage, histological subtype, palliative care referral, length of first line chemotherapy and lines of treatment) and chemotherapy use in the last month of life was determined.

Results

A total of 147 MPM patients were included in the analysis: 78 received chemotherapy, 50 had radiotherapy and 116 had surgery (77 received more than one treatment modality whilst 56 received one treatment modality). Twenty-one patients received treatment in their last month of life: nine received chemotherapy; six, radiotherapy and six had surgery. Those who were treated with second or subsequent lines of chemotherapy were more at risk of receiving chemotherapy until the end of life (six of 19 patients, i.e., 32 %) compared to those who were only treated with first-line therapy (three of 59 patients, i.e., 5 %; p < 0.01). Patients who received chemotherapy at the end of life had shorter survival compared to those who did not receive chemotherapy at the end of life (5.3 vs. 12.5 months, respectively; p = 0.01).

Conclusions

Chemotherapy utilisation in the last month of life is not uncommon in this series of MPM patients. Patients who failed previous chemotherapy were more likely to receive chemotherapy near the end of life. More careful consideration of when to cease chemotherapy needs to be made as patients who received chemotherapy at the end of life had poorer survival outcome.

Keywords

Chemotherapy End of life Malignant pleural mesothelioma Radiotherapy Surgery Treatment utilisation 

References

  1. 1.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644PubMedCrossRefGoogle Scholar
  2. 2.
    van Meerbeeck JP, Gaafar R, Manegold C, van Klaveren RJ, van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Glaccone G, European Organisation for Research and Treatment of Cancer Lung Cancer Group, National Cancer Institute of Canada (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881–6889PubMedCrossRefGoogle Scholar
  3. 3.
    McIllmurray M (2010) The medical treatment of cancer in palliative care. In: Hanks G, Cherny N, Christakis N, Fallon M, Kaasa S, Portenov R (eds) Oxford textbook of palliative Medicine, 4th edn. Oxford University Press, New York, pp 513–525Google Scholar
  4. 4.
    Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK, MS01 Trial Management Group (2008) Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 371:1685–1694PubMedCrossRefGoogle Scholar
  5. 5.
    Australia SW (2011) Mesothelioma in Australia: incidence 1982 to 2007, Mortality 1997 to 2007. Commonwealth of Australia, CanberraGoogle Scholar
  6. 6.
    Kao S, Clarke S, Vardy J, Corte P, Clarke C, van Zandwijk N (2012) Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales of Australia. Intern Med J. doi:10.1111/j.1445-5994.2012.02925.x
  7. 7.
    Fadul N, Elsayem A, Palmer JL, Zhang T, Braiteh F, Bruera E (2007) Predictors of access to palliative care services among patients who died at a Comprehensive Cancer Center. J Palliat Med 10:1146–1152PubMedCrossRefGoogle Scholar
  8. 8.
    Kao S, Shafiq J, Vardy J, Adams D (2009) Use of chemotherapy at end of life in oncology patients. Ann Oncol 20:1555–1559PubMedCrossRefGoogle Scholar
  9. 9.
    Nappa U, Lindqvist O, Rasmussen B, Axelsson B (2011) Palliative chemotherapy during the last month of life. Ann Oncol. doi:10.1093/annonc/mdq778
  10. 10.
    Earle C, Neville B, Landrum M, Ayanian J, Block S, Weeks J (2004) Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22:315–321PubMedCrossRefGoogle Scholar
  11. 11.
    Emanuel E, Young-Xu Y, Levinsky N, Gazelle G, Saynina O, Ash A (2003) Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 138:639–643PubMedCrossRefGoogle Scholar
  12. 12.
    Murillo JJ, Koeller J (2006) Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist 11:1095–1099PubMedCrossRefGoogle Scholar
  13. 13.
    Earle C, Park E, Lai B, Weeks J, Ayanian J, Block S (2003) Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol 21:1133–1138PubMedCrossRefGoogle Scholar
  14. 14.
    Barbera L, Paszat L, Chartier C (2006) Indicators of poor quality end-of-life cancer care in Ontario. J Palliat Care 22:12–17PubMedGoogle Scholar
  15. 15.
    Kao S, Vardy J, Chatfield M, Corte P, Pavlakis N, Clarke C, van Zandwijk N, Clarke S (2012) Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer. doi:10.1016/j.cllc.2012.03.011
  16. 16.
    Australian Bureau of Statistics (2003) ASGC Remoteness Classification: purpose and use (Census Paper No. 03/01). Commonwealth of Australia, CanberraGoogle Scholar
  17. 17.
    Bydder S, Phillips M, Joseph DJ, Cameron F, Spry NA, DeMelker Y, Musk AW (2004) A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 91:9–10PubMedCrossRefGoogle Scholar
  18. 18.
    Boutin C, Rey F, Viallat J-R (1995) Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. Chest 108:754–758PubMedCrossRefGoogle Scholar
  19. 19.
    O'Rourke N, Garcia JC, Paul J, Lawless C, McMenemin R, Hill J (2007) A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 84:18–22PubMedCrossRefGoogle Scholar
  20. 20.
    Zauderer MG, Sima CS, Ginsberg MS, Krug LM (2012) Lack of response to vinorelbine in patients with previously treated malignant pleural mesothleioma (MPM): rational for placebo-controlled trials in the 2nd line setting. 11th International Conference of the International Mesothelioma Interest Group, Boston, Abstr IB.7Google Scholar
  21. 21.
    Temel J, Greer J, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Piri WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742PubMedCrossRefGoogle Scholar
  22. 22.
    Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW (2008) Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135:620–625PubMedCrossRefGoogle Scholar
  23. 23.
    Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ (2008) Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 26:3860–3866PubMedCrossRefGoogle Scholar
  24. 24.
    Hawley R, Monk A (2004) Malignant mesothelioma: current practice and research directions. Collegian 11:22–26CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Steven C. Kao
    • 1
    • 2
    • 3
  • Nico van Zandwijk
    • 1
    • 3
  • Peter Corte
    • 4
  • Christopher Clarke
    • 1
  • Stephen Clarke
    • 3
    • 5
  • Janette Vardy
    • 2
    • 3
    • 6
  1. 1.Asbestos Diseases Research InstituteRhodesAustralia
  2. 2.Department of Medical Oncology, Sydney Cancer CentreSydneyAustralia
  3. 3.Faculty of Medicine, University of SydneyCamperdownAustralia
  4. 4.Department of Respiratory Medicine, Royal Prince Alfred HospitalCamperdownAustralia
  5. 5.Department of Medical Oncology, Royal North Shore HospitalSt. LeonardsAustralia
  6. 6.Department of Medical Oncology, Concord Repatriation General HospitalConcordAustralia

Personalised recommendations